Operating Lease, Right-of-Use Asset of Revance Therapeutics, Inc. from 31 Dec 2018 to 30 Sep 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Revance Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2018 to 30 Sep 2024.
  • Revance Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2024 was $47,996,000, a 12% decline year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Revance Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2024 $47,996,000 -$6,814,000 -12% 30 Sep 2024 10-Q 07 Nov 2024 2024 Q3
Q2 2024 $49,746,000 +$15,308,000 +44% 30 Jun 2024 10-Q 08 Aug 2024 2024 Q2
Q1 2024 $70,245,000 +$32,346,000 +85% 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q4 2023 $53,167,000 +$13,944,000 +36% 31 Dec 2023 10-Q 07 Nov 2024 2024 Q3
Q3 2023 $54,810,000 +$14,288,000 +35% 30 Sep 2023 10-Q 08 Nov 2023 2023 Q3
Q2 2023 $34,438,000 -$7,364,000 -18% 30 Jun 2023 10-Q 08 Aug 2023 2023 Q2
Q1 2023 $37,899,000 -$5,153,000 -12% 31 Mar 2023 10-Q 09 May 2023 2023 Q1
Q4 2022 $39,223,000 -$5,117,000 -12% 31 Dec 2022 10-K 28 Feb 2024 2023 FY
Q3 2022 $40,522,000 -$5,011,000 -11% 30 Sep 2022 10-Q 08 Nov 2022 2022 Q3
Q2 2022 $41,802,000 -$4,532,000 -9.8% 30 Jun 2022 10-Q 09 Aug 2022 2022 Q2
Q1 2022 $43,052,000 +$14,273,000 +50% 31 Mar 2022 10-Q 10 May 2022 2022 Q1
Q4 2021 $44,340,000 +$14,708,000 +50% 31 Dec 2021 10-K 28 Feb 2023 2022 FY
Q3 2021 $45,533,000 +$20,087,000 +79% 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $46,334,000 +$20,968,000 +83% 30 Jun 2021 10-Q 05 Aug 2021 2021 Q2
Q1 2021 $28,779,000 +$2,818,000 +11% 31 Mar 2021 10-Q 10 May 2021 2021 Q1
Q4 2020 $29,632,000 +$3,101,000 +12% 31 Dec 2020 10-K 28 Feb 2022 2021 FY
Q3 2020 $25,446,000 -$1,632,000 -6% 30 Sep 2020 10-Q 09 Nov 2020 2020 Q3
Q2 2020 $25,366,000 -$2,236,000 -8.1% 30 Jun 2020 10-Q 06 Aug 2020 2020 Q2
Q1 2020 $25,961,000 -$2,144,000 -7.6% 31 Mar 2020 10-Q 07 May 2020 2020 Q1
Q4 2019 $26,531,000 +$26,531,000 31 Dec 2019 10-K 25 Feb 2021 2020 FY
Q3 2019 $27,078,000 30 Sep 2019 10-Q 04 Nov 2019 2019 Q3
Q2 2019 $27,602,000 30 Jun 2019 10-Q 06 Aug 2019 2019 Q2
Q1 2019 $28,105,000 31 Mar 2019 10-Q 09 May 2019 2019 Q1
Q4 2018 $0 31 Dec 2018 10-K 26 Feb 2020 2019 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.